Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

LivaNova Launches RECOVER Trial Of VNS For Depression To Meet CMS CED Requirement

Apr 02 2019

• By Reed Miller

• Source: LivaNova PLC

Related Content

Vagus Nerve Stim Gets New Chance To Prove Its Worth For Depression

Feb 15 2019

“Ordered, Intimidated And Coerced”? CDRH Targeted In Misconduct Probe

Nov 24 2008

LivaNova Builds Strategic Base And Commercial Case To Silence Skeptics

Oct 23 2017

CMS denies coverage for VNS Therapy depression indication

May 07 2007

Related Companies

LivaNova PLC

Additional Topics

Research & Development Clinical Trials Reimbursement Commercial Tracking Trials Neurology Medical Device

More from R&D

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.